Novo Nordisk to showcase late-stage pipeline & semaglutide expansion at ADA 2026

The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs

Novo Nordisk study exposes “hidden” inflammation driving cardio risk despite care

POSEIDON is among the largest global datasets to quantify this residual inflammatory burden

Oral GLP-1 race heats up as Lilly’s Foundayo shines in seniors

The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks

Eli lilly’s retatrutide delivers up to 30% weight loss in phase 3 trial

Clears major obesity endpoints at 80 weeks

Lilly's retatrutide delivers 30% weight loss in Phase 3 TRIUMPH-1 trial

All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks

Novo Nordisk unveils breakthrough MASH data as ‘silent’ liver disease threatens 250 million

Mankind launches ‘Act at 30’ campaign to push early heart health screening

Nationwide preventive health initiative aims to make cardiovascular screening at age 30 a standard healthcare milestone

Experts calls for urgent preventive action as hypertension cases rise

Union Minister Prataprao Jadhav terms hypertension a “silent killer”; experts push for early screening, lifestyle correction and wellness-focused healthcare

Lilly and UNICEF launch $50M push to reach 30 million children with life-saving health care

The target reach is of more than 30 million young people and caregivers across 21 countries

Wegovy delivers consistent weight loss & heart benefits for women across menopause: Novo Nordisk study

Nearly one in five women worldwide are now living with obesity